Four Alzheimer’s Clinical Trial Volunteers Honored with National Citizen Scientist Awards® for Their Work in Search of a Cure

Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – andizucchi@rational360.com, 360-927-8767  Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the […]

Read more »

MedVadis Research Joins GAP-Net in Fight to Accelerate Alzheimer’s Treatment

MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022)  – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research  has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private […]

Read more »

“Punitive, restrictive and unprecedented”: Global Alzheimer’s Platform Foundation President® John Dwyer Comments on CMS Draft National Coverage Determination

Dwyer calls on Centers for Medicare & Medicaid Services  to provide coverage for the entire class of mAb drugs approved by the Food &  Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire […]

Read more »

Clinicians and Researchers Urge CMS to Reform Decision to Limit Coverage of Alzheimer’s Treatments

Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]

Read more »

Global Alzheimer’s Platform Foundation® Applauds Neurologists for Speaking Out Against Proposed CMS Plan to Restrict Coverage to Alzheimer’s Patients

New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]

Read more »

STATEMENT: Global Alzheimer’s Platform Foundation® Applauds Biogen for 18 Percent Diversity Recruitment Goal for Participants in Aduhelm Confirmatory Trial

Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]

Read more »

Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans

GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]

Read more »

Global Alzheimer’s Platform Foundation® Applauds Biogen for Reducing Cost of ADUHELM

GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]

Read more »

Atlanta Metro Communities Gain Access to Renowned Alzheimer’s Research Network Through Local Clinical Trial Site

iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]

Read more »

Orlando Seniors Gain Access to Innovative Alzheimer’s Clinical Trial

Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]

Read more »

Global Alzheimer’s Platform Foundation (GAP) Taps Leading International Clinical Trial Expert for Senior Advisor Role

Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]

Read more »

To Beat Alzheimer’s, Tampa Seniors From Underserved Communities can get Involved in Clinical Trials

GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]

Read more »

Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study

Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]

Read more »

Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval

Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]

Read more »

Bio-Hermes Clinical Trial Launches to Compare Biomarker Tests; Seeks Rapid, Less Expensive Diagnostics for Alzheimer’s Disease

Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]

Read more »

Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]

Read more »

Statement to the FDA on Support for Aducanumab for Treatment of Early Stage AD

GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]

Read more »

Lilly’s TRAILBLAZER-ALZ 2 Trial is Partnering with the Global Alzheimer’s Platform Foundation® to Shatter the Slow Completion Timeframes of Alzheimer’s Clinical Trials

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

Read more »

STATEMENT: ELI LILLY’S PHASE 2 DONANEMAB STUDY RESULT IS CAUSE FOR CELEBRATION

Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]

Read more »

STATEMENT: BIOGEN AND APPLE PARTNERSHIP SPEEDS SEARCH FOR ALZHEIMER’S TEST; SHOULD PRIORITIZE DIVERSITY

Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI):  Today’s announcement by Biogen and Apple marks a significant step on the path to early […]

Read more »

Investment in Diversity and Rapid, Early Diagnostics Is Essential to the Search for a Cure for Alzheimer’s Disease

Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]

Read more »

STATEMENT: NEW DATA PLATFORM WILL EXPEDITE INNOVATION AND DRIVE COLLABORATION FOR ALZHEIMER’S DISEASE RESEARCH

Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly […]

Read more »

Global Alzheimer’s Platform Foundation® President Testifies before FDA Advisory Committee in Support of Breakthrough Alzheimer’s Drug

GAP President John Dwyer says aducanumab offers disease-modifying benefit significantly exceeding current therapies Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (November 6, 2020) – Today, the President of the Global Alzheimer’s Platform Foundation® (GAP), John Dwyer, testified before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee regarding Biogen’s breakthrough Alzheimer’s drug aducanumab. Given that clinical […]

Read more »

STATEMENT: BLOOD TEST FOR ALZHEIMER’S IS A MAJOR ADVANCEMENT FOR PATIENTS, RESEARCHERS & PHYSICIANS

Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test. “Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform […]

Read more »
To top